Dai Chihara1, Evgeny Arons2, Maryalice Stetler-Stevenson3, Constance M Yuan3, Hao-Wei Wang3, Hong Zhou2, Mark Raffeld3, Liqiang Xi3, Seth M Steinberg4, Julie Feurtado5, Lacey James2, Wyndham Wilson6, Raul C Braylan7, Katherine R Calvo7, Irina Maric7, Alina Dulau-Florea7, Robert J Kreitman1,2. 1. Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD. 5. Office of Research Nursing, National Cancer Institute, National Institutes of Health, Bethesda, MD. 6. Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 7. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Abstract
PURPOSE:Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-term results are unknown and optimal timing of rituximab undefined. PATIENTS AND METHODS: Patients were randomly assigned to first-line cladribine 0.15 mg/kg intravenously days 1-5 with 8 weekly doses of rituximab 375 mg/m2 begun either day 1 (concurrent, CDAR) or ≥ 6 months later (delayed) after detection of MRD in blood. MRD tests included blood and bone marrow (BM) flow cytometry, and BM immunohistochemistry. RESULTS:Sixty-eight patients with purine analog-naïve classic HCL were randomly assigned 1:1 to concurrent versus delayed arms. At 6 months after CDAR versus cladribine monotherapy, CR rates were 100% versus 88% (P = .11), MRD-free CR rates 97% versus 24% (P < .0001, primary end point), and blood MRD-free rates 100% versus 50% (P < .0001), respectively. At 96 months median follow-up, 94% versus 12% remained MRD free. Compared with CDAR, delayed rituximab after cladribine achieved lower rate (67% of 21 evaluable patients; P = .0034) and durability (P = .0081, hazard radio favoring CDAR, 0.094) of MRD-free CR. Nevertheless, 12 patients in the delayed arm remained MRD free when restaged 6-104 (median, 78) months after last delayed rituximab treatment. Compared with cladribine monotherapy, CDAR led to brief grade 3/4 thrombocytopenia (59% v 9%; P < .0001) and platelet transfusions without bleeding (35% v 0%; P = .0002), but higher neutrophil (P = .017) and platelet (P = .0015) counts at 4 weeks. CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less so by delayed rituximab. Longer follow-up will determine if MRD-free survival leads to less need for additional therapy or cure of HCL.
RCT Entities:
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-term results are unknown and optimal timing of rituximab undefined. PATIENTS AND METHODS: Patients were randomly assigned to first-line cladribine 0.15 mg/kg intravenously days 1-5 with 8 weekly doses of rituximab 375 mg/m2 begun either day 1 (concurrent, CDAR) or ≥ 6 months later (delayed) after detection of MRD in blood. MRD tests included blood and bone marrow (BM) flow cytometry, and BM immunohistochemistry. RESULTS: Sixty-eight patients with purine analog-naïve classic HCL were randomly assigned 1:1 to concurrent versus delayed arms. At 6 months after CDAR versus cladribine monotherapy, CR rates were 100% versus 88% (P = .11), MRD-free CR rates 97% versus 24% (P < .0001, primary end point), and blood MRD-free rates 100% versus 50% (P < .0001), respectively. At 96 months median follow-up, 94% versus 12% remained MRD free. Compared with CDAR, delayed rituximab after cladribine achieved lower rate (67% of 21 evaluable patients; P = .0034) and durability (P = .0081, hazard radio favoring CDAR, 0.094) of MRD-free CR. Nevertheless, 12 patients in the delayed arm remained MRD free when restaged 6-104 (median, 78) months after last delayed rituximab treatment. Compared with cladribine monotherapy, CDAR led to brief grade 3/4 thrombocytopenia (59% v 9%; P < .0001) and platelet transfusions without bleeding (35% v 0%; P = .0002), but higher neutrophil (P = .017) and platelet (P = .0015) counts at 4 weeks. CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less so by delayed rituximab. Longer follow-up will determine if MRD-free survival leads to less need for additional therapy or cure of HCL.
Authors: M S Tallman; D Hakimian; K J Kopecky; S Wheaton; E Wollins; K Foucar; P A Cassileth; T Habermann; M Grever; J M Rowe; L C Peterson Journal: Clin Cancer Res Date: 1999-07 Impact factor: 12.531
Authors: M Grever; K Kopecky; M K Foucar; D Head; J M Bennett; R E Hutchison; W E Corbett; P A Cassileth; T Habermann; H Golomb Journal: J Clin Oncol Date: 1995-04 Impact factor: 44.544
Authors: William G Wierda; John C Byrd; Jeremy S Abramson; Seema Bhat; Greg Bociek; Danielle Brander; Jennifer Brown; Asher Chanan-Khan; Steve E Coutre; Randall S Davis; Christopher D Fletcher; Brian Hill; Brad S Kahl; Manali Kamdar; Lawrence D Kaplan; Nadia Khan; Thomas J Kipps; Jeffrey Lancet; Shuo Ma; Sami Malek; Claudio Mosse; Mazyar Shadman; Tanya Siddiqi; Deborah Stephens; Nina Wagner; Andrew D Zelenetz; Mary A Dwyer; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2017-11 Impact factor: 11.908
Authors: Mojca Jongen-Lavrencic; Tim Grob; Diana Hanekamp; François G Kavelaars; Adil Al Hinai; Annelieke Zeilemaker; Claudia A J Erpelinck-Verschueren; Patrycja L Gradowska; Rosa Meijer; Jacqueline Cloos; Bart J Biemond; Carlos Graux; Marinus van Marwijk Kooy; Markus G Manz; Thomas Pabst; Jakob R Passweg; Violaine Havelange; Gert J Ossenkoppele; Mathijs A Sanders; Gerrit J Schuurhuis; Bob Löwenberg; Peter J M Valk Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: Robert J Kreitman; Wyndham Wilson; Katherine R Calvo; Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Hong Zhou; Mark Raffeld; Maryalice Stetler-Stevenson Journal: Clin Cancer Res Date: 2013-11-25 Impact factor: 12.531
Authors: Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour Journal: Cancer Date: 2021-10-06 Impact factor: 6.860
Authors: Michael Grever; Leslie Andritsos; Versha Banerji; Jacqueline C Barrientos; Seema Bhat; James S Blachly; Timothy Call; Matthew Cross; Claire Dearden; Judit Demeter; Sasha Dietrich; Brunangelo Falini; Francesco Forconi; Douglas E Gladstone; Alessandro Gozzetti; Sunil Iyengar; James B Johnston; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Francesco Lauria; Gerard Lozanski; Sameer A Parikh; Jae Park; Aaron Polliack; Farhad Ravandi; Tadeusz Robak; Kerry A Rogers; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine S Tam; Enrico Tiacci; Xavier Troussard; Clive Zent; Thorsten Zenz; Pier Luigi Zinzani; Bernhard Wörmann Journal: Leukemia Date: 2021-05-04 Impact factor: 11.528
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388